Nocturia
Conditions
Keywords
Nocturnal polyuria
Brief summary
The objective of this study is to find out what the pharmacodynamic (PD) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children). The main questions the investigators want to answer are: * Are differences related to the pathophysiological factors involved in nocturia? * Are there age/gender/size differences? * Can the investigators identify patients who are likely to develop hyponatraemia? * Can the investigators individualize treatment and reduce risk for hyponatraemia? The patient will be given a prescription to buy Minirin Melt 60µg at the local pharmacy. During 30 days, the patient has to take Minirin Melt 60µg in the evening before going to bed. There are two groups of patients: Group A: Patients that still have to undergo an evaluation phase, according to standard procedures (e.g. osmolality test, blood sample). This procedure is not a part of this study. The study starts when the 1st Minirin Melt tablet has been taken (= day 1). Group B: This group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed Minirin Melt 60 µg ambulatory. The study starts when the patients takes his first prescribed Minirin Melt tablet: * On day 3 and day 7 a blood sample will be taken at the UZ Ghent for safety control (Na+, K+, creatinin, osmolality = good clinical practice guideline). These first 2 visits (day 3 and day 7) are standard procedure. If the patient is at high risk for side effects, blood has to be taken during the first 7 days. * On day 3 the patient has to give a urine sample. * Patients have to fill out a frequency/volume chart during the first 14 days. * On day 30, a 3rd blood sample will be taken
Interventions
DRUGDesmopressin
Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
Sponsors
University Hospital, Ghent
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* written informed consent prior to the performance of any study-related activity * patients, men and women, 18 years and older, with an average of ≥ 2 nocturnal voids per night * evidence for nocturnal polyuria (nocturnal urine volume \>33% of total volume over 24h), determined on frequency/volume chart * Diuresis \<2.5L
Exclusion criteria
* hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances * pregnancy * genitourinary tract pathology (infection, tumor,...) * urolithiasis * suspicion or evidence of cardiac failure * moderate to severe renal insufficiency (creatinin clearance \< 60 ml/min) * psychogenic or habitual polydipsia * hyponatraemia or predisposition for hyponatraemia * diabetes insipidus * syndrome of inadequate ADH production * suspicion or evidence of liver failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 3. | At day 3 after first desmopressin intake. | — |
| Urine sample for urine concentration of Na+, K+, creatinin and osmolality | At day 3 | — |
| Area Under Curve (AUC) frequency/volume chart during the first 14 days | Every day during the first 14 days. | — |
| The decrease of number of nocturnal micturition episodes. | At day 0 | Questionnaires at day 0 to evaluate the decrease of number of nocturnal micturition episodes. |
| The decrease of the number of nocturnal micturition episodes. | At day 30 | Questionnaires at day 30 to evaluate the number of nocturnal micturition episodes |
| Registration of number of side effects at day 3. | At day 3 | — |
| Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 7. | At day 7 after first desmopressin intake | — |
| Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 30. | At day 30 after first desmopressin intake | — |
| Registration of number of side effects at day 7 | At day 7 | — |
| Registration of number of side effects at day 30. | At day 30 | — |
Countries
Belgium
Outcome results
None listed